Sona Nanotech Inc
CNSX:SONA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sona Nanotech Inc
CNSX:SONA
|
CA |
|
Isiklar Enerji ve Yapi Holding AS
IST:IEYHO.E
|
TR |
|
Everbright Grand China Assets Ltd
HKEX:3699
|
HK |
|
Osaka Titanium Technologies Co Ltd
TSE:5726
|
JP |
|
Huber+Suhner AG
LSE:0QNH
|
CH |
|
H
|
Hap Seng Plantations Holdings Bhd
KLSE:HSPLANT
|
MY |
|
B
|
Bellavista Resources Ltd
ASX:BVR
|
AU |
|
Watkin Jones PLC
LSE:WJG
|
UK |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
CN |
|
E
|
Energa SA
WSE:ENG
|
PL |
|
Renishaw PLC
LSE:RSW
|
UK |
|
JTEKT India Ltd
NSE:JTEKTINDIA
|
IN |
|
Harbin Pharmaceutical Group Co Ltd
SSE:600664
|
CN |
Sona Nanotech Inc
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
